Madrigal Pharmaceuticals, Inc. MDGL
433.03 USD +0.43 (+0.10%)
At closeNov 11, 2026, 4:00 PM EST
425.20 -7.83 -1.81%
After hours · Nov 11, 4:00 PM ET
431.55 Day range 440.00
353.54 52-week range 615.00
- YTD
- -25.64%
- 1 year
- -20.03%
News
prnewswire.com Investigation of MDGL Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP RADNOR, Pa., Nov. 11, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the…
globenewswire.com Kaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Investigation of Possible Securities Law Violations NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ:…
businesswire.com MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 8.1% Share Drop NEW YORK--(BUSINESS WIRE)---- $MDGL #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Madrigal Pharmaceuticals, Inc. (“Madrigal” or the…
prnewswire.com MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns /PRNewswire/ -- Hagens Berman, a national complex securities litigation law firm, announces an investigation into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
newsfilecorp.com Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (MDGL) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation New York, New York--(Newsfile Corp. - November 11, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
globenewswire.com MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national complex securities litigation law firm, announces an investigation into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL). The…
zacks.com 4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
newsfilecorp.com Kaplan Fox Alerts Madrigal Pharmaceuticals, Inc. (MDGL) Investors to an Investigation of Potential Securities Law Violations New York, New York--(Newsfile Corp. - November 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
globenewswire.com Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law Violations NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ:…
defenseworld.net Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Lessened by Candriam S.C.A. Candriam S.C.A. trimmed its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 4.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities…
newsfilecorp.com Kaplan Fox Announces a Securities Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) - Investors Encouraged to Contact the Firm New York, New York--(Newsfile Corp. - November 9, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
businesswire.com MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $MDGL--MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
globenewswire.com MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP RADNOR, Pa., Nov. 07, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the…
prnewswire.com Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP RADNOR, Pa., Nov. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the…
businesswire.com NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the…
businesswire.com Lost Money on Madrigal Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 8.1% Share Price Drop LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP…
businesswire.com Did You Lose Money on Madrigal Pharmaceuticals, Inc. Stock? The Law Offices of Howard G. BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard…
newsfilecorp.com Kaplan Fox & Kilsheimer LLP Encourages Madrigal Pharmaceuticals, Inc. (MDGL) Investors to Contact the Firm Regarding Potential Securities Law Violations New York, New York--(Newsfile Corp. - November 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company")…
businesswire.com Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. LOS ANGELES--(BUSINESS WIRE)--Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today…
globenewswire.com Kaplan Fox & Kilsheimer LLP Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law Violations NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ:…
benzinga.com Madrigal Pharmaceuticals Announces Data From Its Rezdiffra Trials Demonstrated 55% Participants Achieved Over 25% Improvement In Liver Stiffness, 48% Patients Reports Over 30% Improvement At 12 Months Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced…
globenewswire.com Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra CONSHOHOCKEN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q4 Healthcare stocks Alnylam, Madrigal and Corcept appear oversold, with RSI near or below 30, offering potential opportunities for investors.
defenseworld.net Reviewing Madrigal Pharmaceuticals (NASDAQ:MDGL) & OSR (NASDAQ:OSRH) Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and OSR (NASDAQ: OSRH - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies…
benzinga.com Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633 Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $612 to $633.
benzinga.com Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743 Truist Securities analyst Srikripa Devarakonda reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $709 to $743.
benzinga.com Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $760 Citigroup analyst Eric Joseph maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $725 to $760.
benzinga.com Madrigal Pharmaceuticals Q3 2026 Earnings Call Transcript Madrigal Pharmaceuticals (NASDAQ:MDGL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Madrigal Pharmaceuticals Q3 EPS $1.83 Beats $(0.94) Estimate, Sales $431.268M Beat $404.264M Estimate Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $(0.94) by 294.68 percent. This is a 136.02 percent increase over…